PubMed
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (FOXO4-DRI)
Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 56% · Mixed 34% · Unfavorable overall 10%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.1–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 66% said they felt similar to their last entry, 30% more positive, and 16% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 159 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 49% · Mixed 42% · Unfavorable overall 9%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg
Reports span 0.025–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 59% said they felt similar to their last entry, 35% more positive, and 19% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 30 days · Based on 190 repeat reporters
Published sources linked on the FOXO4-DRI and NAD+ wiki pages.
PubMed
Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017
PubMed
Born E, Lipskaia L, Breau M, et al. Circulation. 2023
PubMed
Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017
PubMed
Covarrubias AJ, Perrone R, Grozio A, et al. Nat Rev Mol Cell Biol. 2021
PubMed
Reiten OK, Wilvang MA, Mitchell SJ, et al. J Clin Invest. 2021
PubMed
Yoshino J, Baur JA, Imai SI. Cell Metab. 2018
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Bhasin S, Seals D, Migaud M, et al. Endocrine reviews. 2023
PubMed
Verdin E. Science (New York, N.Y.). 2015
PubMed
Imai S, Guarente L. Trends in cell biology. 2014
PubMed
Song Q, Zhou X, Xu K, et al. Advances in nutrition (Bethesda, Md.). 2023